Zhong Jianfeng, Li Bing
Department of Neurosurgery, Affiliated Yan'an Hospital of Kunming Medical University, Kunming 650051, China.
Department of Neurosurgery, Affiliated Yan'an Hospital of Kunming Medical University, Kunming 650051, China.
J Clin Neurosci. 2015 Mar;22(3):583-7. doi: 10.1016/j.jocn.2014.09.013. Epub 2015 Jan 3.
MicroRNA-134 (miR-134) has been demonstrated to be dysregulated in glioma tissues. However, its clinical significance in this tumor type has not been fully elucidated. This study was designed to explore the association of miR-134 expression with clinicopathological features and prognosis in human glioma. Using real-time quantitative polymerase chain reaction, miR-134 expression was detected in 162 glioma specimens with various World Health Organization (WHO) grades and compared to the expression in 36 normal brain tissue samples. Glioma tissues exhibited significantly reduced expression of miR-134 (mean 2.15 ± standard deviation 0.82 versus 4.37 ± 1.16, p<0.001) compared with normal brain tissues. In addition, miR-134 expression was notably associated with WHO grade (p<0.001) and Karnofsky Performance Scale score (KPS; p=0.02) in glioma tissues. Low miR-134 expression occurred more frequently in glioma tissues with high WHO grades and low KPS scores. In univariate analysis, both progression-free survival (PFS) and overall survival (OS) of glioma patients with low miR-134 expression were significantly shorter than those with high miR-134 expression (both p<0.001). Additionally, glioma patients with high WHO grades, low KPS scores and subtotal resection attained significantly poorer PFS (p<0.001, 0.02 and 0.01, respectively) and OS (p<0.001, 0.01 and 0.01, respectively). In multivariate analysis, miR-134 expression, WHO grade, KPS score and extent of resection were identified as the independent prognostic factors for both PFS and OS. Collectively, our data prove that the reduced expression of miR-134 may predict aggressive progression and poor prognosis in human gliomas. miR-134 may represent both a prognostic marker and a novel therapeutic target for this malignancy.
微小RNA-134（miR-134）已被证明在胶质瘤组织中表达失调。然而，其在这种肿瘤类型中的临床意义尚未完全阐明。本研究旨在探讨miR-134表达与人类胶质瘤临床病理特征及预后的关系。采用实时定量聚合酶链反应，检测了162例不同世界卫生组织（WHO）分级的胶质瘤标本中miR-134的表达，并与36例正常脑组织样本中的表达进行比较。与正常脑组织相比，胶质瘤组织中miR-134的表达显著降低（平均值2.15±标准差0.82，而正常脑组织为4.37±1.16，p<0.001）。此外，miR-134的表达与胶质瘤组织中的WHO分级（p<0.001）和卡氏功能状态评分（KPS；p=0.02）显著相关。miR-134低表达在WHO分级高和KPS评分低的胶质瘤组织中更常见。单因素分析显示，miR-134低表达的胶质瘤患者的无进展生存期（PFS）和总生存期（OS）均显著短于miR-134高表达的患者（均p<0.001）。此外，WHO分级高、KPS评分低和次全切除的胶质瘤患者的PFS（分别为p<0.001、0.02和0.01）和OS（分别为p<0.001、0.01和0.01）显著较差。多因素分析表明，miR-134表达、WHO分级、KPS评分和切除范围是PFS和OS的独立预后因素。总体而言，我们的数据证明miR-134表达降低可能预示人类胶质瘤的侵袭性进展和不良预后。miR-134可能代表这种恶性肿瘤的预后标志物和新型治疗靶点。
